全文获取类型
收费全文 | 16746篇 |
免费 | 1543篇 |
国内免费 | 37篇 |
专业分类
耳鼻咽喉 | 160篇 |
儿科学 | 544篇 |
妇产科学 | 295篇 |
基础医学 | 2150篇 |
口腔科学 | 300篇 |
临床医学 | 1836篇 |
内科学 | 3238篇 |
皮肤病学 | 191篇 |
神经病学 | 1600篇 |
特种医学 | 679篇 |
外科学 | 2512篇 |
综合类 | 370篇 |
一般理论 | 19篇 |
预防医学 | 1580篇 |
眼科学 | 453篇 |
药学 | 1251篇 |
中国医学 | 11篇 |
肿瘤学 | 1137篇 |
出版年
2022年 | 166篇 |
2021年 | 362篇 |
2020年 | 212篇 |
2019年 | 349篇 |
2018年 | 427篇 |
2017年 | 298篇 |
2016年 | 332篇 |
2015年 | 370篇 |
2014年 | 484篇 |
2013年 | 658篇 |
2012年 | 1055篇 |
2011年 | 1056篇 |
2010年 | 558篇 |
2009年 | 458篇 |
2008年 | 878篇 |
2007年 | 877篇 |
2006年 | 866篇 |
2005年 | 807篇 |
2004年 | 813篇 |
2003年 | 680篇 |
2002年 | 693篇 |
2001年 | 428篇 |
2000年 | 403篇 |
1999年 | 349篇 |
1998年 | 177篇 |
1997年 | 151篇 |
1996年 | 150篇 |
1995年 | 109篇 |
1994年 | 131篇 |
1993年 | 134篇 |
1992年 | 320篇 |
1991年 | 289篇 |
1990年 | 258篇 |
1989年 | 244篇 |
1988年 | 220篇 |
1987年 | 207篇 |
1986年 | 196篇 |
1985年 | 173篇 |
1984年 | 130篇 |
1983年 | 109篇 |
1982年 | 96篇 |
1981年 | 84篇 |
1980年 | 106篇 |
1979年 | 97篇 |
1978年 | 93篇 |
1977年 | 91篇 |
1976年 | 89篇 |
1974年 | 90篇 |
1973年 | 111篇 |
1972年 | 91篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Whitney S. Brandt Wanpu Yan Jian Zhou Kay See Tan Joseph Montecalvo Bernard J. Park Prasad S. Adusumilli James Huang Matthew J. Bott Valerie W. Rusch Daniela Molena William D. Travis Mark G. Kris Jamie E. Chaft David R. Jones 《The Journal of thoracic and cardiovascular surgery》2019,157(2):743-753.e3
Objective
Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.Methods
Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.Results
In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.Conclusions
Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection. 相似文献3.
4.
5.
William G. Breen Krishan R. Jethwa Nathan Y. Yu Grant M. Spears William S. Harmsen Robert C. Miller Jonathan B. Ashman William G. Rule Terence T. Sio Michelle A. Neben-Wittich Michael G. Haddock Amit Mahipal Mark J. Truty Christopher L. Hallemeier Kenneth W. Merrell 《Practical radiation oncology》2021,11(1):e63-e69
PurposeOur purpose was to determine the effect of chemoradiotherapy (CRT) on patient-reported quality of life (QOL) for patients with intact pancreas cancer.Methods and MaterialsWe reviewed a prospective QOL registry for patients with intact, clinically localized pancreatic ductal adenocarcinoma treated with CRT between June 2015 and November 2018. QOL was assessed pre-CRT (immediately before CRT, after neoadjuvant chemotherapy) and at the completion of CRT with the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) and its component parts: FACT-General (FACT-G) and hepatobiliary cancer subscore (HCS). A minimally important difference from pre-CRT was defined as ≥ 6, 5, and 8 points for FACT-G, HCS, and FACT-Hep, respectively.ResultsOf 157 patients who underwent CRT, 100 completed both pre- and post-CRT surveys and were included in the primary analysis. Median age at diagnosis was 65 years (range, 23-90). National Comprehensive Cancer Network resectability status was resectable (3%), borderline resectable (40%), or locally advanced (57%). Folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) (75%) or gemcitabine and nab-paclitaxel (42%) were given for a median of 6 cycles (range, 0-42) before CRT. Radiation therapy techniques included 3-dimensional conformal (22%), intensity modulated photon (55%), and intensity modulated proton (23%) radiation therapy to a median dose of 50 Gy (range, 36-62.5). Concurrent chemotherapy was most commonly capecitabine (82%). Sixty-three patients (63%) had surgery after CRT. The mean decline in FACT-G, HCS subscale, and FACT-Hep from pre- to post-CRT was 3.5 (standard deviation [SD], 13.7), 1.7 (SD 7.8), and 5.2 (SD 19.4), respectively. Each of these changes were statistically significant, but did not meet the minimally important difference threshold. Pancreatic head tumor location was associated with decline in FACT-Hep. Nausea was the toxicity with the greatest increase from pre- to post-CRT by both physician-assessment and patient-reported QOL.ConclusionsFor patients with intact pancreatic adenocarcinoma, modern CRT is well tolerated with minimal decline in QOL during treatment. 相似文献
6.
7.
8.
9.
Aurora Perez-Cornago Georgina K. Fensom Colm Andrews Eleanor L. Watts Naomi E. Allen Richard M. Martin Mieke Van Hemelrijck Timothy J. Key Ruth C. Travis 《British journal of cancer》2020,123(12):1808
Background Although prostate cancer is a leading cause of cancer death, its aetiology is not well understood. We aimed to identify novel biochemical factors for prostate cancer incidence and mortality in UK Biobank.Methods A range of cardiovascular, bone, joint, diabetes, renal and liver-related biomarkers were measured in baseline blood samples collected from up to 211,754 men at recruitment and in a subsample 5 years later. Participants were followed-up via linkage to health administrative datasets to identify prostate cancer cases. Hazard ratios (HRs) and 95% confidence intervals were calculated using multivariable-adjusted Cox regression corrected for regression dilution bias. Multiple testing was accounted for by using a false discovery rate controlling procedure.Results After an average follow-up of 6.9 years, 5763 prostate cancer cases and 331 prostate cancer deaths were ascertained. Prostate cancer incidence was positively associated with circulating vitamin D, urea and phosphate concentrations and inversely associated with glucose, total protein and aspartate aminotransferase. Phosphate and cystatin-C were the only biomarkers positively and inversely, respectively, associated with risk in analyses excluding the first 4 years of follow-up. There was little evidence of associations with prostate cancer death.Conclusion We found novel associations of several biomarkers with prostate cancer incidence. Future research will examine associations by tumour characteristics.Subject terms: Predictive markers, Prostate cancer, Risk factors 相似文献
10.